Initially developed as a Haspin inhibitor (124, 125), LDN192960 inhibited DYRK2 with 13 nM IC50 and exhibited antitumor activity in mouse models of MM and TNBC (26). This evidence concerns the gene DYRK2 and Miyoshi myopathy.